ClinConnect ClinConnect Logo
Search / Trial NCT06663670

Intraneural Facilitation Therapy and Nerve Flossing Technique in Patients With Diabetic Peripheral Neuropathy

Launched by RIPHAH INTERNATIONAL UNIVERSITY · Oct 28, 2024

Trial Information

Current as of July 22, 2025

Not yet recruiting

Keywords

Diabetes Mellitus Type 2 Diabetic Neuropathy Endoneurium Epineurium Gait Pain Peripheral Nerve Quality Of Life

ClinConnect Summary

This clinical trial is looking at two different treatment methods—intraneural facilitation therapy and nerve flossing technique—to see how they affect people with diabetic peripheral neuropathy (DPN). DPN is a condition that can cause symptoms like numbness, tingling, burning, or sharp pain in the feet and legs, which can make it hard to walk and can affect overall quality of life. The goal of the study is to find out which of these therapies is more effective in reducing pain, improving balance and walking, and enhancing the quality of life for those affected by this condition.

To participate in this trial, you need to have a diagnosis of type 2 diabetes and specific symptoms of neuropathy, such as tingling or pain below the ankle. However, the study is not open to individuals with other serious health issues, like severe kidney problems or autoimmune diseases, and those who have had foot ulcers or amputations recently. If eligible, participants will receive one of the two therapies and will have the chance to share their experiences regarding their symptoms and daily activities. This study is currently not recruiting participants, but it aims to provide valuable insights into better treatment options for those living with diabetic peripheral neuropathy.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Type 2 diabetes mellitus (diagnosed by the physician)
  • Score \>3 on Michigan Neuropathy Screening Instrument-Questionnaire and score \>2 on MNSI-Physical Examination
  • Diabetic peripheral neuropathy symptoms below the ankle (numbness, tingling, burning, sharp pain, increased sensitivity, etc.)
  • Exclusion Criteria:
  • Presence of any other systemic disease rather than diabetes such as end-stage renal failure, uncontrolled hypertension, severe dyslipidemia, chronic liver disease, autoimmune disease, advanced chronic obstructive pulmonary disease, etc.
  • Diabetic ulcer in either foot
  • Total or partial amputation of lower extremities
  • Active inflammations or other inflammatory neuropathies including chronic inflammatory demyelinating polyneuropathy, proximal diabetic neuropathy, chemotherapy-induced peripheral neuropathy, autonomic neuropathies, or other neuropathies not associated with DM such as B12 deficiency
  • History of fracture, strain, history of trauma leading to nerve injuries in the last year.

About Riphah International University

Riphah International University is a leading educational institution based in Pakistan, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to excellence in research and education, Riphah emphasizes ethical standards and scientific integrity in its clinical studies. The university collaborates with various stakeholders, including healthcare professionals and industry partners, to enhance patient outcomes and contribute to the global body of medical knowledge. Through its robust research programs, Riphah International University aims to foster a culture of inquiry and improve healthcare delivery both locally and internationally.

Locations

Gujranwala, Punjab, Pakistan

Gujranwala, Punjab, Pakistan

Patients applied

0 patients applied

Trial Officials

Hira Jabeen, MS-NMPT

Study Chair

Riphah International University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported